{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+risperidone&page=2", "query": { "intervention": "Oral risperidone", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+risperidone&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T12:18:13.384Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01222975", "title": "Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranbaxy Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2004-10", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2010-10-18", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222975" }, { "nct_id": "NCT01086748", "title": "A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LY2140023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Denovo Biopharma LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1134, "start_date": "2010-03", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 19, "location_summary": "Escondido, California • Garden Grove, California • Paramount, California + 16 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086748" }, { "nct_id": "NCT02431702", "title": "A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia", "Psychotic Disorders" ], "interventions": [ { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Oral Paliperidone ER", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Oral Risperidone", "type": "DRUG" }, { "name": "Paliperidone Palmitate Injection (PP1M)", "type": "DRUG" }, { "name": "Paliperidone Palmitate Injection (PP3M)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 337, "start_date": "2015-07-08", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 34, "location_summary": "Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431702" }, { "nct_id": "NCT03893825", "title": "A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "TV-46000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "13 Years to 65 Years" }, "enrollment_count": 336, "start_date": "2019-04-17", "completion_date": "2021-12-02", "has_results": true, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 67, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893825" }, { "nct_id": "NCT01222923", "title": "Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranbaxy Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-10", "completion_date": "2005-01", "has_results": false, "last_update_posted_date": "2010-10-18", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222923" }, { "nct_id": "NCT05179525", "title": "Comparative Bioavailability of Risperidone.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Risperidone ISM® 100 mg", "type": "DRUG" }, { "name": "Risperdal 4mg Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rovi Pharmaceuticals Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 80, "start_date": "2021-03-09", "completion_date": "2021-09-17", "has_results": false, "last_update_posted_date": "2022-01-05", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 4, "location_summary": "Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Gaithersburg", "state": "Maryland" }, { "city": "Berlin", "state": "New Jersey" }, { "city": "DeSoto", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05179525" }, { "nct_id": "NCT02019329", "title": "A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "RO5545965", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 32, "start_date": "2014-01", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02019329" }, { "nct_id": "NCT00946985", "title": "28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "paliperidone palmitate", "type": "DRUG" }, { "name": "oral risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ortho-McNeil Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 163, "start_date": "2009-06", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2012-09-10", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Garden Grove, California • San Diego, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Kissimmee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00946985" }, { "nct_id": "NCT04524403", "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antipsychotic-induced Weight Gain (AIWG)" ], "interventions": [ { "name": "Miricorlilant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2020-09-09", "completion_date": "2022-08-25", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 40, "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04524403" }, { "nct_id": "NCT01171937", "title": "Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "8 Years to 16 Years" }, "enrollment_count": 41, "start_date": "2008-09", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2022-05-17", "last_synced_at": "2026-09-26T12:18:13.384Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01171937" } ] }